Amplification of FRS2 in atypical lipomatous tumour/well‐differentiated liposarcoma and de‐differentiated liposarcoma: a clinicopathological and genetic study of 146 cases

Abstract

These findings suggest that FRS2 is amplified consistently in ALT/WDL/DDLs and offer another avenue for the investigation of the biology of this tumour group. MDM2 /FRS2 cases seem to be associated with certain clinicopathological features, and further investigation is needed.

Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients

“…Contrary to our findings, a recent study found that FRS2 knockdown promotes tumor progression in two NB cell lines . However, FRS2 is amplified in many cancer types so FRS2 presents typical oncogenic features . Furthermore, the focal amplification of 12q15 region in many cancers, as in primary NB tissues, is correlated with increased mRNA expression of FRS2 , suggesting a functional relevance of the copy number gain.…”

“…37 However, FRS2 is amplified in many cancer types so FRS2 presents typical oncogenic features. [20][21][22][23][24][25][26][27] Furthermore, the focal amplification of 12q15 region in many cancers, as in primary NB tissues, is correlated with increased mRNA expression of FRS2, suggesting a functional relevance of the copy number gain.…”

“…Molecular genomic profiling by array‐comparative genome hybridization (a‐CGH) of tumor tissues biobanked at the time of diagnosis here lead us to describe the occurrence of a new, sporadic fibroblast growth factor receptor substrate 2 ( FRS2 ) gene amplification distinct from MYCN . Previous studies have found that abnormal activation of the FRS2 gene is related to tumorigenesis in some cancers . We have also used public available transcriptomics data to evaluate the transcriptional consequences of FRS2 amplification for NB patients.…”

“…Previous studies have found that abnormal activation of the FRS2 gene is related to tumorigenesis in some cancers. [20][21][22][23][24][25][26][27] We have also used public available transcriptomics data to evaluate the transcriptional consequences of FRS2 amplification for NB patients.…”

A Case of Atypical Lipomatous Tumor that Dedifferentiated with Second Recurrence after Additional Resection

“…A liposarcoma is a malignant mesenchymal tumor that can present as an atypical lipomatous tumor, well-differentiated liposarcoma, dedifferentiated liposarcoma, myxoid liposarcoma, and pleomorphic liposarcoma [ 1 ]. In 1979, Evans suggested that a dedifferentiated liposarcoma was similar to a differentiated adipose sarcoma [ 2 ], which frequently occurs in limbs and the retroperitoneum and is more likely to affect patients aged 40 to 60 years [ 1 , 3 ]. The dedifferentiated tumor is generally well understood but it is very rare; it occurs in less than 5% of well-differentiated liposarcomas and rare tissue types [ 4 ].…”